Cardiovascular Biology Laboratory, ICGEB Trieste, Trieste, Italy.
Cardiovascular Biology Laboratory, ICGEB Trieste, Trieste, Italy; University of Trieste, Department of Medicine, Surgery and Health Sciences, Trieste, Italy.
Trends Pharmacol Sci. 2022 Nov;43(11):894-905. doi: 10.1016/j.tips.2022.06.001. Epub 2022 Jun 29.
Biologics are revolutionizing the treatment of chronic diseases, such as cancer and monogenic disorders, by overcoming the limits of classic therapeutic approaches using small molecules. However, the clinical use of biologics is limited for cardiovascular diseases (CVDs) , which are the primary cause of morbidity and mortality worldwide. Here, we review the state-of-the-art use of biologics for cardiac disorders and provide a framework for understanding why they still struggle to enter the field. Some limitations are common and intrinsic to all biological drugs, whereas others depend on the complexity of cardiac disease. In our opinion, delineating these struggles will be valuable in developing and accelerating the approval of a new generation of biologics for CVDs.
生物制剂正在通过克服使用小分子的经典治疗方法的局限性，彻底改变癌症和单基因疾病等慢性疾病的治疗方式。然而，生物制剂在心血管疾病（CVD）中的临床应用受到限制，CVD 是全世界发病率和死亡率的主要原因。在这里，我们回顾了生物制剂在心脏疾病中的最新应用，并提供了一个框架来理解为什么它们仍然难以进入该领域。一些局限性是所有生物药物共有的常见和内在的，而另一些则取决于心脏疾病的复杂性。在我们看来，明确这些挑战对于开发和加速新一代 CVD 生物制剂的批准将是有价值的。
